Working… Menu

A Study of LY3295668 Erbumine in Participants With Relapsed/Refractory Neuroblastoma

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details. Identifier: NCT04106219
Recruitment Status : Recruiting
First Posted : September 26, 2019
Last Update Posted : April 8, 2021
New Approaches to Neuroblastoma Therapy Consortium (NANT)
Innovative Therapies for Children with Cancer in Europe (ITCC)
Information provided by (Responsible Party):
Eli Lilly and Company

No Study Results Posted on for this Study
Recruitment Status : Recruiting
Estimated Primary Completion Date : April 17, 2024
Estimated Study Completion Date : April 18, 2025